Aravive Inc

Aravive, Inc. operates as a clinical stage biotechnology company. The firm engages in the development of new therapies that target important survival pathways for both advanced solid tumors as well as hematologic malignancies. Its product candidate, Aravive-S6, is a soluble Fc-fusion protein designed to block the activation of the GAS6-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL which also promotes metastasis, cancer cell survival, resistance to treatments and immune suppression. The company was founded on December 10, 2008 and is headquartered in Houston, TX.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Aravive Biologics is a clinical-stage biotechnology company that focuses on developing therapies that target important survival pathways for both solid tumors as well as hematologic malignancies.

HOUSTON, March 31, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced fourth quarter and full year ended December 31, 2021 financial results and provided corporate updates.

Aravive Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Updates

HOUSTON, March 30, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, announced today that it has entered into definitive agreements with a single healthcare-focused institutional investor and Eshelman Ventures, LLC for the issuance and sale of an aggregate of 4,850,241 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 4,850,241 shares of common stock in a registered direct offering priced at-the-market under Nasdaq rules. The purchase price per share and accompanying warrant is $2.005 for the institutional investor and $2.325 for Eshelman Ventures, LLC.

Aravive Announces $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

HOUSTON, March 07, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer of Aravive, will participate in an in-person fireside chat at the 34th Annual ROTH Conference on Monday, March 14, 2022, at 8:30 am PT in HEALTHCARE VFC – Suite 2022 at The Ritz Carlton, Dana Point, California. Dr. McIntyre and Vinay Shah, Chief Financial Officer of Aravive, will be available for one-on-one meetings on Monday, March 14th.

Aravive to Participate In-Person at 34th Annual ROTH Conference

Aravive Inc (NASDAQ: ARAV) has announced new data from the Phase 1b portion of the ongoing Phase 1b/2 trial of batiraxcept in clear cell renal cell cancer (ccRCC). 26 previously treated ccRCC patients have been treated with batiraxcept at doses of 15 mg/kg (n=16) and 20 mg/kg (n=10.

Aravive Highlights Updated Batiraxcept Data From Kidney Cancer Trial

HOUSTON, March 02, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, will present updated exposure-response analyses from the Phase 1b platinum-resistant ovarian cancer and Phase 1b clear cell renal cancer trials at the American Association for Cancer Research (AACR) annual meeting taking place between April 8-13, 2022 in New Orleans, Louisiana. The abstract presentation at AACR will be presented virtually.

Aravive to Present Updated Modeling Data from Batiraxcept Clinical Trials at the AACR Annual Meeting

Here is how Aravive (ARAV) and Cerner (CERN) have performed compared to their sector so far this year.

Is Aravive (ARAV) Stock Outpacing Its Medical Peers This Year?

Aravive (ARAV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Aravive (ARAV) Upgraded to Buy: Here's Why

Here is how Aravive (ARAV) and Catalyst Pharmaceutical (CPRX) have performed compared to their sector so far this year.

Is Aravive (ARAV) Outperforming Other Medical Stocks This Year?

Preliminary top line data anticipated throughout 2022 Preliminary top line data anticipated throughout 2022

Aravive Announces First Patient Dosed in Phase 2 Study of Batiraxcept in Clear Cell Renal Cell Carcinoma

HOUSTON, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease today announced that the company's Chairman, Fred Eshelman, Pharm.D., through Eshelman Ventures, LLC, agreed to purchase a pre-funded warrant to purchase 4,545,455 shares of the company's common stock at a price of $2.20 per share, which was the consolidated closing bid price of the company's common stock on The Nasdaq Global Select Market on December 31, 2021. The investment strengthens the company's balance sheet by approximately $10.0 million, enhancing the company's financial flexibility and liquidity ahead of multiple anticipated clinical milestones throughout 2022 for each of the company's clinical programs. The investment is expected to close on January 5, 2022.

Aravive Announces $10.0 Million Investment by Eshelman Ventures, LLC and Appointment of Dr. Eshelman as Executive Chairman of the Aravive Board of Directors

HOUSTON, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative, targeted therapeutics to treat life-threatening cancers, today announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer of Aravive, and Reshma Rangwala, M.D., Ph.D., Chief Medical Officer of Aravive, will participate in a virtual fireside chat at the Piper Sandler 33rd Annual Healthcare Conference taking place November 29 – December 2, 2021. Aravive's presentation will be available for viewing on November 22, 2021 at 10:00 AM ET. Aravive will also participate in virtual one-on-one meetings on December 1, 2021.

Aravive to Participate in Fireside Chat at Piper Sandler 33rd Annual Virtual Healthcare Conference

3 of 5 (60%) patients achieved a partial response All 5 patients treated demonstrated tumor decrease from baseline Batiraxcept has been generally well-tolerated with no dose-limiting toxicities Aravive to host conference call and webcast on November 12 at 8:30 a.m. ET to discuss updated data

Aravive Announces Positive Preliminary Data from Phase 1b Trial Evaluating Batiraxcept (AVB-500) in Combination with Cabozantinib in Clear Cell Renal Cell Carcinoma to be Presented at 2021 Society for Immunotherapy of Cancer Annual Meeting

HOUSTON, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative, targeted therapeutics to treat life-threatening cancers, today announced recent corporate updates and financial results for the third quarter ended September 30, 2021.

Aravive Reports Third Quarter 2021 Financial Results and Provides Corporate Updates

HOUSTON, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer of Aravive, and Reshma Rangwala, M.D., Ph.D., Chief Medical Officer of Aravive, will participate in a virtual fireside chat at the Cantor Fitzgerald Virtual Global Healthcare Conference on September 30, 2021 at 9:20 AM ET. Aravive will also participate in one-on-one meetings at the conference.

Aravive to Participate in Fireside Chat at Cantor Fitzgerald Virtual Global Healthcare Conference

HOUSTON, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer of Aravive, and Reshma Rangwala, M.D., Ph.D., Chief Medical Officer of Aravive, will participate in a virtual fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021. The Company's presentation will be available for viewing on September 13, 2021 at 7:00 AM ET. Aravive will also participate in one-on-one meetings at the conference.

Aravive to Participate in Fireside Chat at H.C. Wainwright 23rd Annual Global Investment Conference

Trial to Evaluate AVB-500 as a First-Line Treatment in Combination with Gemcitabine and Nab-Paclitaxel

Aravive Announces First Patient Dosed in Phase 1b/2 Clinical Trial of AVB-500 for the Treatment of Pancreatic Adenocarcinoma

HOUSTON, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced recent corporate updates and financial results for the second quarter ended June 30, 2021.

Aravive Reports Second Quarter 2021 Financial Results and Provides Corporate Updates

HOUSTON, July 27, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer of Aravive, and Reshma Rangwala, M.D., Ph.D., Chief Medical Officer of Aravive, will participate in a virtual fireside chat at the 2021 BTIG Biotechnology Conference on August 9, 2021, at 9:30 AM ET. Aravive will also be participating in one-on-one meetings at the conference.

Aravive to Participate in Fireside Chat at 2021 BTIG Biotechnology Conference

Milestone is Based on Approval of 3D Medicines' IND in China to Participate in Aravive's AVB-500 (3D-299) Phase 3 Clinical Trial for Platinum Resistant Ovarian Cancer Milestone is Based on Approval of 3D Medicines' IND in China to Participate in Aravive's AVB-500 (3D-299) Phase 3 Clinical Trial for Platinum Resistant Ovarian Cancer

Aravive Achieves Second Development Milestone from 3D Medicines

HOUSTON, July 07, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced that Gail McIntyre, Ph.D., DBAT, Chief Executive Officer of Aravive, and Reshma Rangwala, M.D., Ph.D., Chief Medical Officer of Aravive, will participate in a virtual fireside chat at the 2021 William Blair Biotech Focus Conference on July 15, 2021, at 3:00 PM ET. Aravive will also be participating in one-on-one meetings at the conference.

Aravive to Participate in Fireside Chat at 2021 William Blair Biotech Focus Conference

Aravive (ARAV) delivered earnings and revenue surprises of 2.22% and -54.69%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Aravive (ARAV) Reports Q1 Loss, Lags Revenue Estimates

Addresses High Unmet Medical Need for Women with Advanced Ovarian Cancer

Aravive Announces First Patient Dosed in Phase 3 Registrational Trial Evaluating AVB-500 in Patients with Platinum Resistant Ovarian Cancer

HOUSTON, March 12, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq:ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced that updated data from its Phase 1b trial evaluating AVB-500 in platinum resistant ovarian cancer (PROC) will be presented at the 2021 Society of Gynecologic Oncology Annual Meeting on Women's Cancer. Additionally, a trial in progress poster will be presented on an open label Phase 1/2 investigator-sponsored trial of AVB-500 in combination with durvalumab in patients with platinum resistant, recurrent epithelial ovarian cancer. The meeting is being held virtually on March 19-25, 2021.

Aravive to Present Phase 1b Data Evaluating AVB-500 in Platinum Resistant Ovarian Cancer at 2021 Society of Gynecologic Oncology Annual Meeting

Bumble

NextEra Energy

Wheaton Precious Metals

Akebia Therapeutics

BeiGene

Imperial Oil

Iovance Biotherapeutics

loanDepot

With the trading day about halfway over, the broad markets were pushing higher on the day.

Bumble, NextEra Energy, Wheaton Precious Metals and More Monday Afternoon Analyst Calls

HOUSTON, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced that it has entered into a securities purchase agreement with Eshelman Ventures, LLC to sell 2,875,000 shares of common stock at a price of $7.29 per share in a registered direct offering. Aravive expects to receive gross proceeds of approximately $21.0 million from this offering. Eshelman Ventures, LLC is an entity wholly-owned by Fredric N. Eshelman, Pharm.D., chairman of Aravive's Board of Directors.

News for Aravive Inc Stock (ARAV)